These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26132521)

  • 41. Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor.
    Herbein G; Montaner LJ; Gordon S
    J Virol; 1996 Nov; 70(11):7388-97. PubMed ID: 8892857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles.
    Mahajan SD; Roy I; Xu G; Yong KT; Ding H; Aalinkeel R; Reynolds J; Sykes D; Nair BB; Lin EY; Prasad PN; Schwartz SA
    Curr HIV Res; 2010 Jul; 8(5):396-404. PubMed ID: 20426757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
    Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
    J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functionalized, Long-Circulating, and Ultrasmall Gold Nanocarriers for Overcoming the Barriers of Low Nanoparticle Delivery Efficiency and Poor Tumor Penetration.
    Lee KY; Lee GY; Lane LA; Li B; Wang J; Lu Q; Wang Y; Nie S
    Bioconjug Chem; 2017 Jan; 28(1):244-252. PubMed ID: 27341302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
    Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.
    Fiandra L; Capetti A; Sorrentino L; Corsi F
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):17-30. PubMed ID: 27832401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 7,8-secolignans from Schisandra wilsoniana and their anti-HIV-1 activities.
    Zhang XJ; Yang GY; Wang RR; Pu JX; Sun HD; Xiao WL; Zheng YT
    Chem Biodivers; 2010 Nov; 7(11):2692-701. PubMed ID: 21072768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiretroviral activity of thiosemicarbazone metal complexes.
    Pelosi G; Bisceglie F; Bignami F; Ronzi P; Schiavone P; Re MC; Casoli C; Pilotti E
    J Med Chem; 2010 Dec; 53(24):8765-9. PubMed ID: 21121632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delivery of antisense peptide nucleic acid by gold nanoparticles for the inhibition of virus replication.
    Ghaffari E; Rezatofighi SE; Ardakani MR; Rastegarzadeh S
    Nanomedicine (Lond); 2019 Jul; 14(14):1827-1840. PubMed ID: 31274375
    [No Abstract]   [Full Text] [Related]  

  • 53. [Study of biological properties of HIV-1 variants resistant to antiretroviral preparations].
    Nikonorova IuV; Unagaeva NV; Bogachev VV; Baryshev PB; Meshcheriakova IuV; Chernousova NIa; Gashnikova NM
    Zh Mikrobiol Epidemiol Immunobiol; 2012; (6):52-6. PubMed ID: 23297632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gold manno-glyconanoparticles for intervening in HIV gp120 carbohydrate-mediated processes.
    Di Gianvincenzo P; Chiodo F; Marradi M; Penadés S
    Methods Enzymol; 2012; 509():21-40. PubMed ID: 22568899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and anti-HIV activity of some [Nucleoside Reverse Transcriptase Inhibitor]-C5'-linker-[Integrase Inhibitor] heterodimers as inhibitors of HIV replication.
    Sugeac E; Fossey C; Ladurée D; Schmidt S; Laumond G; Aubertin AM
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):497-509. PubMed ID: 15662954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
    Buzón MJ; Codoñer FM; Frost SD; Pou C; Puertas MC; Massanella M; Dalmau J; Llibre JM; Stevenson M; Blanco J; Clotet B; Paredes R; Martinez-Picado J
    PLoS Pathog; 2011 Oct; 7(10):e1002314. PubMed ID: 22046128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.
    Gunaseelan S; Gunaseelan K; Deshmukh M; Zhang X; Sinko PJ
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):518-31. PubMed ID: 19941919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin.
    Bhumkar DR; Joshi HM; Sastry M; Pokharkar VB
    Pharm Res; 2007 Aug; 24(8):1415-26. PubMed ID: 17380266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles: A promising in vivo drug delivery system for colorectal cancer therapy.
    Lee CS; Kim H; Yu J; Yu SH; Ban S; Oh S; Jeong D; Im J; Baek MJ; Kim TH
    Eur J Med Chem; 2017 Dec; 142():416-423. PubMed ID: 28870452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.